Search results for "carbonic anhydrase"

showing 10 items of 65 documents

N-Substituted and ring opened saccharin derivatives selectively inhibit transmembrane, tumor-associated carbonic anhydrases IX and XII.

2017

A series of N-substituted saccharins incorporating aryl, alkyl and alkynyl moieties, as well as some ring opened derivatives were prepared and investigated as inhibitors of the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1). The widespread cytosolic isoforms CA I and II were not inhibited by these sulfonamides whereas transmembrane, tumor-associated ones were effectively inhibited, with KIs in the range of 22.1-481nM for CA IX and of 3.9-245nM for hCA XII. Although the inhibition mechanism of these tertiary/secondary sulfonamides is unknown for the moment, the good efficacy and especially selectivity for the inhibition of the tumor-associated over the cytosolic, widespread isoforms, make…

Gene isoformStereochemistryClinical BiochemistryPharmaceutical Science01 natural sciencesBiochemistrychemistry.chemical_compoundStructure-Activity RelationshipSaccharinAntigens NeoplasmCarbonic anhydraseDrug DiscoveryHumansCarbonic Anhydrase IXCarbonic Anhydrase InhibitorsMolecular BiologyAlkylCarbonic Anhydraseschemistry.chemical_classificationbiologyDose-Response Relationship DrugMolecular Structure010405 organic chemistryArylOrganic ChemistryTransmembrane protein0104 chemical sciences010404 medicinal & biomolecular chemistryCytosolEnzymechemistryBiochemistrybiology.proteinMolecular MedicineSelectivityBioorganicmedicinal chemistry
researchProduct

3H-1,2-benzoxathiepine 2,2-dioxides: a new class of isoform-selective carbonic anhydrase inhibitors

2017

Abstract A new chemotype with carbonic anhydrase (CA, EC 4.2.1.1) inhibitory action has been discovered, the homo-sulfocoumarins (3H-1,2-benzoxathiepine 2,2-dioxides) which have been designed considering the (sulfo)coumarins as lead molecules. An original synthetic strategy of a panel of such derivatives led to compounds with a unique inhibitory profile and very high selectivity for the inhibition of the tumour associated (CA IX/XII) over the cytosolic (CA I/II) isoforms. Although the CA inhibition mechanism with these new compounds is unknown for the moment, we hypothesize that it may be similar to that of the sulfocoumarins, i.e. hydrolysis to the corresponding sulfonic acids which therea…

Gene isoformStereochemistryHigh selectivityInhibitory postsynaptic potential01 natural sciencesStructure-Activity RelationshipHydrolysisCarbonic anhydraseDrug DiscoveryHumansMoleculeCarbonic Anhydrase InhibitorsCarbonic AnhydrasesPharmacologyCarbonic anhydraseDose-Response Relationship DrugMolecular Structurebiology010405 organic chemistryChemistrylcsh:RM1-950Active sitehomo-sulfocoumarinsGeneral MedicineCyclic S-Oxides0104 chemical sciencesinhibitor010404 medicinal & biomolecular chemistryCytosollcsh:Therapeutics. PharmacologyBiochemistrysulfocoumarinbiology.proteinResearch PaperJournal of Enzyme Inhibition and Medicinal Chemistry
researchProduct

The shell-forming proteome of Lottia gigantea reveals both deep conservations and lineage-specific novelties

2013

19 pages; International audience; Proteins that are occluded within the molluscan shell, the so-called shell matrix proteins (SMPs), are an assemblage of biomolecules attractive to study for several reasons. They increase the fracture resistance of the shell by several orders of magnitude, determine the polymorph of CaCO(3) deposited, and regulate crystal nucleation, growth initiation and termination. In addition, they are thought to control the shell microstructures. Understanding how these proteins have evolved is also likely to provide deep insight into events that supported the diversification and expansion of metazoan life during the Cambrian radiation 543 million years ago. Here, we p…

Glycoside Hydrolasesmedicine.medical_treatmentproteomeGastropodaMolecular Sequence DataBiologyBiochemistrymollusc shell matrix proteinsTranscriptomeCyclophilins03 medical and health sciencesPaleontologyLineage specificAnimal ShellsSequence Analysis ProteinTandem Mass Spectrometry[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]evolutionmedicineAnimalsAmino Acid Sequence14. Life underwaterMantle (mollusc)[SDV.IB.BIO]Life Sciences [q-bio]/Bioengineering/BiomaterialsMolecular BiologyCarbonic Anhydrases030304 developmental biologyExtracellular Matrix Proteins0303 health sciencesProteaseEpidermal Growth FactorSequence Homology Amino AcidLimpet030302 biochemistry & molecular biologyCell Biologybiology.organism_classification[ SDV.IB.BIO ] Life Sciences [q-bio]/Bioengineering/BiomaterialsbiomineralizationPeptide FragmentsProtein Structure TertiaryPeroxidasesEvolutionary biology[ SDV.BBM.GTP ] Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]ProteomeLottia giganteaElectrophoresis Polyacrylamide GelmantleBiomineralization
researchProduct

The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications.

2002

Adjunctive therapy for the management of glaucoma is commonly used. Unfixed combinations of the prostaglandin analog latanoprost and other glaucoma medications have been demonstrated to effectively lower intraocular pressure (IOP). The range of reported additional reductions in IOP compared to a monotherapy baseline are as follows: latanoprost-timolol (13-37%), latanoprost-pilocarpine 2% (7-14%), latanoprost and carbonic anhydrase inhibitors (15-24.1%), and latanoprost and dipivefrin (15-28%). There is a fixed combination of latanoprost (0.005%) and timolol (0.5%) that has been investigated in Phase III trials in Europe and the United States. In these trials, it was noted that the efficacy …

Intraocular pressureMydriaticsgenetic structuresCombination therapymedicine.medical_treatmentAdrenergic beta-AntagonistsTimololGlaucomachemistry.chemical_compoundMedicineHumansLatanoprostCarbonic Anhydrase InhibitorsAntihypertensive AgentsIntraocular PressureChemotherapyDipivefrinbusiness.industryGlaucomamedicine.diseaseeye diseasesOphthalmologyProstaglandin analogchemistryAnesthesiaProstaglandins F SyntheticLatanoprostDrug Therapy CombinationOcular Hypertensionsense organsOphthalmic SolutionsSafetybusinessmedicine.drugSurvey of ophthalmology
researchProduct

Update on topical carbonic anhydrase inhibitors

2001

Topical carbonic anhydrase inhibitors are a novel addition to the armamentarium of medical glaucoma treatment; dorzolamide has been available since 1995 and brinzolamide since 1998. They lower intraocular pressure by inhibiting carbonic anhydrase, a key enzyme for aqueous humor formation. Intraocular pressure-lowering activity of the substances appears to be the same and is similar to that of most other agents, but it does not reach the activity of the unselective beta-blocker timolol or the prostaglandin latanoprost. On concomitant treatment, additivity is reached with all other topical agents. A possible improvement of blood flow may offer an additional benefit, but its significance for t…

Intraocular pressuregenetic structuresBrinzolamideThiazinesGlaucomaTimololThiophenesPharmacologyEyeAqueous Humorchemistry.chemical_compoundDorzolamideCarbonic anhydrasemedicineHumansLatanoprostCarbonic Anhydrase InhibitorsAntihypertensive AgentsIntraocular PressureCarbonic Anhydraseschemistry.chemical_classificationSulfonamidesDose-Response Relationship Drugbiologybusiness.industryGlaucomaGeneral Medicinemedicine.diseaseeye diseasesOphthalmologyEnzymechemistryProstaglandins F Syntheticbiology.proteinLatanoprostsense organsOphthalmic SolutionsbusinessBlood Flow Velocitymedicine.drugCurrent Opinion in Ophthalmology
researchProduct

Addition of a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension

2011

Katrin Lorenz1, Klaus Rosbach2, Andreas Matt3, Norbert Pfeiffer11University Medical Center, Johannes Gutenberg-Universität Mainz, Mainz, Germany; 2Private practice, Mainz, Germany; 3Private practice, Köln-Hohenhaus, GermanyBackground: This study was conducted to evaluate the safety and efficacy of adding a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin analog (PGA) monotherapy in patients with primary open-angle glaucoma, pigment dispersion glaucoma, or ocular hypertension who require additional intraocular pressure (IOP) reduction.Methods: This was a prospective, multicenter (n = 5), open-label, single-arm, Phase IV clinical trial in which patients cur…

Intraocular pressuremedicine.medical_specialtygenetic structuresadjunctive therapyfixed combinationBrinzolamideTimololGlaucomaOcular hypertensionOphthalmologyMedicineAdverse effectcarbonic anhydrase inhibitorOriginal Researchbusiness.industryClinical OphthalmologyRE1-994medicine.diseasebrinzolamideeye diseasesDiscontinuationOphthalmologyProstaglandin analogglaucomasense organsbusinessmedicine.drugintraocular pressureClinical Ophthalmology
researchProduct

Interaction of sulphate and chloride with cobalt(II)-carbonic anhydrase

1990

The interaction between Cobalt(II)-Bovine Carbonic Anhydrase II and the inhibitors sulphate and chloride have been investigated through 1H NMR and electronic absorption spectroscopies. Both inhibitors bind to the metal ion forming a 1:1 adduct and the corresponding affinity constants have been determined. These inhibitors interact weakly with CoBCA II and this interaction only occurs at low pH values. The T1 values of the meta-like protons of the coordinated histidines have been measured. The coordination number of the metal ion in the adducts is discussed on the basis of temperature dependence of the isotropic shifts, T1, and molar absorbance values.

Magnetic Resonance SpectroscopyCarbonic anhydrase IICoordination numberInorganic chemistryIon chromatographychemistry.chemical_elementBiochemistryChlorideAdductInorganic ChemistryChloridesCarbonic anhydrasemedicineCarbonic Anhydrase InhibitorsCarbonic AnhydrasesbiologySulfatesChemistryOsmolar ConcentrationTemperatureCobaltHydrogen-Ion ConcentrationSpectrophotometrybiology.proteinProton NMRCobaltmedicine.drugJournal of Inorganic Biochemistry
researchProduct

Nitric oxide modulates cerebral blood flow stimulation by acetazolamide in the rat cortex: a laser Doppler scanning study

2001

Abstract The involvement of nitric oxide (NO) in cerebral blood flow (CBF) stimulation by acetazolamide was studied in anaesthetised, mechanically ventilated Wistar rats. CBF was monitored by laser Doppler scanning. Acetazolamide induced a long-lasting significant rCBF-increase. Application of N G -Nitro- l -arginine (L-NNA), an inhibitor of all NO synthetases (NOS), prevented CBF stimulation by acetazolamide. Continuous infusion of the exogenous NO donor SIN-1 (3-morpholinosydnonimine) suppressed L-NNA induced increases of mean arterial blood pressure without effect on rCBF in comparison to baseline. Additional acetazolamide injection then again caused a significant increase of rCBF in spi…

MaleArginineVasodilator AgentsHemodynamicsBlood PressureStimulationPharmacologyNitric OxideNitroarginineNitric oxidechemistry.chemical_compoundLaser-Doppler FlowmetrymedicineAnimalsNitric Oxide DonorsRats WistarCarbonic Anhydrase InhibitorsCerebral CortexChemistryGeneral NeuroscienceLaser Doppler velocimetryRatsAcetazolamidemedicine.anatomical_structurenervous systemCerebral blood flowCerebral cortexCerebrovascular CirculationMolsidomineAnesthesiaNitric Oxide SynthaseAcetazolamidecirculatory and respiratory physiologymedicine.drugNeuroscience Letters
researchProduct

Acetazolamide treatment for infantile central sleep apnea.

2001

Central sleep apnea is a common respiratory pattern in healthy neonates. Nevertheless, frequent central sleep apnea associated with drops in oxygen saturation may contribute to infantile morbidity. Recently, low-dose acetazolamide was shown to reduce symptomatic central sleep apnea in adults. We treated 12 infants, median conceptional age 42 weeks (range, 40-44 weeks), with central sleep apnea. In all cases, the central apnea index was >40/h total sleeping time (apnea ≥ 3 sec). The cumulative duration of drops in oxygen saturation below 90% was more than 3 min/h total sleeping time. All individuals received acetazolamide 7 mg/kg/day (orally, divided in three doses) for 11 weeks. Polysomn…

MaleCentral sleep apneaPolysomnographyPolysomnography030226 pharmacology & pharmacyDrug Administration ScheduleHypoxemia03 medical and health sciences0302 clinical medicineSleep Apnea SyndromesmedicineHumansOximetryRespiratory systemCarbonic Anhydrase InhibitorsOxygen saturation (medicine)medicine.diagnostic_testbusiness.industry05 social sciencesInfant Newborn050301 educationSleep apneaApneamedicine.diseaseAcetazolamideAnesthesiaPediatrics Perinatology and Child HealthFemaleNeurology (clinical)medicine.symptombusinessAcetazolamide0503 educationmedicine.drugJournal of child neurology
researchProduct

Carbonic anhydrase activity in a calcium-mobilizing epithelium of the crustacean Orchestia cavimana during molting

1987

We investigated the involvement of the enzyme, carbonic anhydrase, in the calcification-decalcification processes occurring in the posterior caeca of the midgut of the terrestrial crustacean, Orchestia cavimana, before and after exuviation. This enzyme was ultrahistochemically localized throughout the membranes of the caecal epithelium as well as extracellularly, i.e., within pre-exuvial calcareous concretions and postexuvial calcified spherules. During the molt cycle, the pattern of carbonic anhydrase activity in the posterior caeca was correlated with the calcium content at this level. Acetazolamide treatment in vivo inhibited about 50% of the calcium uptake during both pre-exuvial secret…

MaleHistologychemistry.chemical_elementCalciumEpitheliumCrustaceaCarbonic anhydrasemedicineAnimalsMolecular BiologyCarbonic Anhydraseschemistry.chemical_classificationbiologyHistocytochemistryReabsorptionMidgutCell BiologyGeneral MedicineEpitheliumAcetazolamideMedical Laboratory Technologymedicine.anatomical_structureEnzymeBiochemistrychemistrybiology.proteinCalciumAnatomyGeneral Agricultural and Biological SciencesAcetazolamideDigestive SystemMoultingmedicine.drugHistochemistry
researchProduct